Western University - Marginalized patients have increased risk of early death from newly diagnosed metastatic breast cancer, study finds - Education News Canada

PALO ALTO, Calif., Oct. 19, 2026 /PRNewswire/ -- Riboscience, a clinical-stage biotechnology company developing first-in-class immunotherapies, today announced that Phase 1b data for RBS2418, its lead oral ENPP1 inhibitor, will be presented in a poster at the European Society for Medical Oncology (ESMO) Congress 2026, held October 23–27 in Madrid, Spain. Title: Overall survival and intratumoral immune activation in subjects with advanced metastatic solid tumors, by Thomas U. Marron, Jamal G. Misleh, Michael Gordon, Zev A. Wainberg, Christopher T. Chen, Daniel Johnson, Alexander I. Spira, Jordan Berlin, Won Jin Ho, John T. Hamm, Ralph V. Boccia, Seol Hee Im, Stephan Rogalla, Juergen Schanzer, Ningwu Huang, Sayantanee Paul, Edward Pham, Buer Song, Jeffrey S. Glenn, Hirak Der-Torossian, Klaus Klumpp and Aaron J. Scott

A new study published in Clinical Cancer Research Title: Second- and third-line outcomes after selective RET inhibitor failure in RET fusion-positive metastatic lung cancer: A real-world analysis from the RET-MAP registry

Results from a recent matching-adjusted indirect comparison (MAIC) analysis indicated clinical favorability of retifanlimab versus avelumab for the treatment of metastatic Merkel cell carcinoma (MCC), which investigators described as “a rare and aggressive skin cancer with poor prognosis and low survival rate. A team of researchers from Italy conducted the study and published their findings in Advances in Therapy. Both retifanlimab and avelumab are classified as monoclonal immune checkpoint inhibitor (ICI) antibodies, and investigators highlighted that both medications are approved for the treatment of metastatic or locally advanced recurrent MCC. They explained that the goal of their research was to assess clinical outcomes of both ICIs via a MAIC analysis of data from the phase 2 POD1UM-201 trial and part B of the phase 2 JAVELIN Merkel 200 trial. Patient data from each trial were used in the analysis, with data from POD1UM-201 informing the retifanlimab group and aggregate data from JAVELIN Merkel 200 informing the avelumab treatment group. Investigators also underscored that the data cutoff of POD1UM-201 was July 2024.

Eugénie Lacroix, a Quebec woman diagnosed with breast cancer at 46 years old, is urging the province to expand access to earlier screening as advocates call for changes to a program that currently targets women aged 50 to 74. Now living with stage 4 breast cancer, Lacroix hopes sharing her experience will push Quebec’s next government to act on recommendations to extend organized screening to younger women.

We report the case of a 19-year-old Saudi man who presented with a four-day history of cough, whitish sputum, and shortness of breath. Despite relatively mild symptoms and preserved oxygen saturation, chest imaging showed extensive bilateral pulmonary calcification. High-resolution computed tomography demonstrated diffuse sand-like calcified micronodules, interlobular septal thickening with a crazy-paving pattern, and the black pleura sign. Bronchoalveolar lavage cytology revealed microliths with multinucleated giant cells, while genetic testing identified a pathogenic variant in the SLC34A2 gene, supporting the diagnosis. In this patient, the relatively mild clinical presentation contrasted with the extensive radiological abnormalities. The complementary findings from imaging, bronchoalveolar lavage cytology, and the available genetic result supported the diagnosis without the need for surgical lung biopsy. Following completion of the diagnostic workup, the patient was referred for lung transplantation evaluation, and genetic screening of family members was recommended.